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Pancreatic ductal adenocarcinoma is the 4th leading cause of cancer-related mortality in 
the US. Most patients present with advanced disease and ~95% die within five years, most 
surviving under six months. Targeted therapies offer modest improvement in survival, albeit at 
an increase in side effects and unwanted toxicities.  
Ref-1 regulates transcription factors involved in pancreatic cancer cell survival signaling 
due to its redox-coactivator activity, such as HIF-1α, NFκB, NRF2 and STAT3. High expression 
levels of Ref-1 indicate decreased survival in PDAC and other cancers. APX3330, a specific 
Ref-1 inhibitor, has been shown in multiple in vitro and in vivo pancreatic cancer models to be 
effective in reducing tumor growth and metastases. The safety and dose administration of 
APX3330 have been previously established, including toxicology, phase I, and phase II clinical 
evaluation in non-cancer patients in Japan (Eisai). We have partnered with ApeX Therapeutics 
to develop APX3330 for cancer treatment (phase I trial anticipated early 2016). 
We studied interactions of Ref-1, APX3330, convergent pathways; i.e. HIF-1α and 
STAT3, and downstream targets like CAIX. We performed in vivo studies demonstrating single 
and combination effects of APX3330 with Gemcitabine (Gem) showing significantly decreased 
tumor volume in the combination treatments. We also tested single and combination studies of 
APX3330 in an ex vivo 3-D tumor-stroma model system using patient derived tumor cells along 
with patient derived cancer-associated fibroblasts. We used the CAIX inhibitor SLC-0111 and 
JAK2 inhibitor, Ruxolitinib; both in clinical trials. In our system, APX3330 decreases the tumor 
area and intensity in a dose-dependent manner. The combination of APX3330 with Gem 
demonstrated an additive enhancement effect in the tumor, and APX3330 with SLC-
0111/Ruxolitinib enhanced tumor killing. These data demonstrate APX3330 single agent 
efficacy in our 3D patient model and enhanced tumor killing when pathways regulated by Ref-1, 
HIF-1 and STAT3 are blocked.  
 
 
